A Study to Assess the Relative Bioavailability of Oral ABBV-932 in Healthy Adult Participants

Phase 1

Recruiting

• Conditions: Healthy Volunteer
• Interventions: Drug: ABBV-932

• Registration Number: NCT06849791
• Lead Sponsor: AbbVie

Brief Summary

This study will assess the relative bioavailability and effect of food on pharmacokinetics of ABBV-932 oral administration in healthy adult participants.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2025-02-24
• Study First Submitted QC: 2025-02-24
• Study Start: 2025-02-26
• Study First Posted: 2025-02-27
• Status Verified: 2025-03
• Last Update Submitted: 2025-03-10
• Last Update Posted: 2025-03-11
• Primary Completion: 2025-12
• Study Completion: 2025-12

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 28

Inclusion Criteria

• Body Mass Index (BMI) ≥ 18.0 to ≤ 32.0 kg/m^2 after rounding to the tenths decimal at the time of screening and upon initial confinement. BMI is calculated as weight in kg divided by the square of height measured in meters.
• A condition of general good health, based upon the results of a medical history, physical examination, vital signs, laboratory profile, and a 12-lead ECG

Exclusion Criteria

• History of epilepsy, any clinically significant cardiac, respiratory (except mild asthma as a child), renal, hepatic, gastrointestinal, hematologic or psychiatric disease or disorder, or any uncontrolled medical illness.
• History of any clinically significant sensitivity or allergy to any medication or food.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: CROSSOVER

Arm && Interventions

Group	Intervention	Description
ABBV-932: Arm E	ABBV-932	Participants will receive a single dose of ABBV-932 Arm E on day 1 with a high-fat meal.
ABBV-932: Arm A	ABBV-932	Participants will receive a single dose of ABBV-932 Arm A on day 1 under fasting conditions.
ABBV-932: Arm C	ABBV-932	Participants will receive a single dose of ABBV-932 Arm C on day 1 under fasting conditions.
ABBV-932: Arm B	ABBV-932	Participants will receive a single dose of ABBV-932 Arm B on day 1 under fasting conditions.
ABBV-932: Arm D	ABBV-932	Participants will receive a single dose of ABBV-932 Arm D on day 1 with a high-fat meal.

Primary Outcome Measures

Name	Time	Method
Maximum Plasma Concentration (Cmax) of ABBV-932	Up to approximately 6 days	Cmax of ABBV-932
Time to Cmax (Tmax) of ABBV-932	Up to approximately 6 days	Tmax of ABBV-932
Terminal Phase Elimination Rate Constant (Beta) of ABBV-932	Up to approximately 6 days	Terminal phase elimination rate constant (beta) of ABBV-932
Terminal Phase Elimination Half-Life (t1/2) of ABBV-932	Up to approximately 6 days	Terminal phase elimination half-life of ABBV-932
Area Under the Concentration-Time Curve From Time 0 to Time t (AUCt) of ABBV-932	Up to approximately 6 days	AUCt of ABBV-932
Area Under the Concentration-Time Curve From Time 0 to Infinity (AUCinf) of ABBV-932	Up to approximately 6 days	AUCinf of ABBV-932
Number of Participants Experiencing Adverse Events	Up to approximately 180 days	An AE is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment.

Trial Locations

Locations (1)

Acpru /Id# 266649; 🇺🇸 Grayslake, Illinois, United States